Clinical trials: Kidney Disorder
Acute Kidney Injury, Acute Interstitial Nephritis
Biorepository to Support Research in Kidney Diseases
To support advances in the understanding of pathophysiology and therapies of kidney diseases by creating a BioBank of kidney tissue, DNA, plasma, and urine from patients with kidney diseases.
- Conditions
- Acute Kidney Injury, Acute Interstitial Nephritis, Kidney Diseases
- Trial name
- NCT04343417
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Yale University
Renal Failure
Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) in Invasive Cardiology
Diagnosis of acute kidney injury (AKI) relies on a late marker, namely serum creatinine (SCr). New biomarkers are considered for early and sensitive detection of CIN.
- Trial name
- NCT01612117
- Where
- Switzerland
- Volunteers
- 244 people
- Sponsor
- University of Freiburg
Fabry Disease
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
Fabry Disease (FD) is a rare X-linked lysosomal storage disorder (LSD) caused by mutations in the GLA gene which translates into decreased activity or lack of function of the enzyme alpha-galactosidase A (α-GAL A) and…
- Trial name
- NCT03228940
- Testing
- RVX000222
- Where
- Canada
- Sponsor
- Resverlogix Corp
Alzheimer's Disease, Huntington's Disease
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
This study is to compare the pharmacokinetics of Dimebon in subjects with severe renal impairment to subjects with normal renal function after oral administration of a single oral 20-mg dose of Dimebon.
- Trial name
- NCT00824590
- Testing
- Dimebon
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Renal Cell Carcinoma
Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC
Metastatic renal cell carcinoma (mRCC) is the most common malignant tumour of the kidneys. Targeted therapies, which were recently introduced in the treatment of mRCC, have become the standard treatment in these patients.
- Trial name
- NCT02315755
- Where
- 19 sites in Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Pfizer
Blood Pressure, Hydration
Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)
Compared with White Adults, Non-Hispanic Black Adults are at an elevated risk of developing cardiovascular disease (CVD) and end stage chronic-kidney disease (CKD), two of the leading causes of death in the United States.
- Conditions
- Blood Pressure, Hydration, Vascular Disease Risk
- Trial name
- PHACKs (NCT06062017)
- Testing
- Water and Potassium supplementation
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Auburn University
Rhabdomyolysis, Myopathy
Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients
1. Analyze the various causes of breakdown of muscle fibers in hospitalized patients. 2. Analyze the characteristics of these patients in Taiwan (including the drugs history, risk factors and the incidence of complications).
- Conditions
- Rhabdomyolysis, Myopathy, Acute Renal Failure, Neuroleptic Malignant Syndrome
- Trial name
- NCT01022450
- Where
- Taiwan
- Volunteers
- 2,500 people
- Sponsor
- National Taiwan University Hospital
End-Stage Renal Disease, Hemodialysis
Hemocontrol and Blood Pressure Control in Dialysis Patients
Volume overload contributes significantly to the pathogenesis of hypertension in hemodialysis patients. The Hemocontrol(HC)system (Gambro), which automatically adjusts ultrafiltration rate and dialysate conductivity according to…
- Trial name
- NCT00319774
- Testing
- Hemocontrol Biofeedback System
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Université de Montréal
CKD Anemia
A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants with chronic kidney disease and not on dialysis.
- Trial name
- NCT01750190
- Testing
- Roxadustat
- Where
- 145 sites in United States, Argentina and 14 more
- Volunteers
- 922 people
- Sponsor
- Kyntra Bio
Chronic Renal Failure
Pulsatile Perfusion Preservation in Kidney Transplantation From Expanded Criteria Donors
Our hypothesis is that the Waters Medical® pulsatile perfusion machine (RM 3) is a way to improve delayed graft function (DGF) in marginal grafts, and some perfusion profiles (flow, pressure, resistance index, venous effluent pH)…
- Trial name
- IMPULSION (NCT01170910)
- Testing
- Static incubation, Pulsatile perfusion
- Where
- France
- Volunteers
- 162 people
- Sponsor
- Hospices Civils de Lyon
Contrast Induced Nephropathy
Efficacy of Alpha Tocopherol for Prevention of Contrast-induced Nephropathy in Chronic Kidney Disease (CKD) Patients
The purpose of this study is to demonstrate the efficacy of alpha tocopherol for prevention contrast-induced nephropathy in CKD patients undergoing elective coronary procedures.
- Trial name
- NCT01061320
- Testing
- alpha tocopherol
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Thammasat University
Complicated Urinary Tract Infection
Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
The purpose of this study is to evaluate the safety and efficacy of intravenous CXA 101 and comparator in complicated urinary tract infection
- Trial name
- NCT00921024
- Testing
- CXA-101, Ceftazidime
- Where
- 21 sites in United States, Germany and 1 more
- Volunteers
- 129 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Shock
Renin-guided Hemodynamic Management in Patients With Shock
Shock is a major risk factor for mortality among patients admitted to intensive care units (ICUs). Since various hemodynamic strategies uniformly delivered to patients with shock have failed to improve clinically relevant…
- Trial name
- RENIN (NCT05898126)
- Testing
- Renin-guided hemodynamic management, Usual care
- Where
- 3 sites in Croatia, Italy
- Volunteers
- 800 people
- Sponsor
- Università Vita-Salute San Raffaele
Chronic Kidney Disease 5D, Uremia; Chronic
ICHARUS: Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms
Background: Many patients receiving maintenance hemodialysis continue to experience persistent uremic symptoms, such as pruritus, fatigue, sleep disorders, reduced physical performance, and impaired quality of life, despite…
- Trial name
- ICHARUS (NCT07522008)
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Azienda Ospedaliera Brotzu
Immunoglobulin A Nephropathy, IgAN
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
- Trial name
- I CAN (NCT06291376)
- Testing
- Ravulizumab
- Where
- 246 sites in United States, Argentina and 26 more
- Volunteers
- 584 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Ovarian Cancer, Fallopian Tube Cancer
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Preclinical and early-phase clinical data suggest that immune modulation represents a treatment strategy that is worthy of further investigation in relapsed epithelial ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Extra Renal Origin
- Trial name
- NCT03355976
- Testing
- Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Brown University
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer that has spread to other places in the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01727076
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Lupus Nephritis
Daratumumab to Treat Active Lupus Nephritis
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.
- Trial name
- NCT04868838
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome
To confirm the efficacy and safety of rituximab (genetical recombination) intravenously administered to idiopathic membranous nephropathy with nephrotic syndrome.
- Trial name
- PRIME (NCT05914155)
- Testing
- Rituximab (genetical recombination)
- Where
- 18 sites in Japan
- Volunteers
- 88 people
- Sponsor
- Shoichi Maruyama MD PhD